TBPH - Theravance Biopharma Inc Stock Price, Fair Value and News

$8.41-0.50 (-5.61%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TBPH Price Action

Last 7 days

-15.8%

Last 30 days

-3.7%

Last 90 days

-11.3%

Trailing 12 Months

-10.4%

TBPH RSI Chart

TBPH Valuation

Market Cap

420.5M

Price/Earnings (Trailing)

-7.21

Price/Sales (Trailing)

6.44

EV/EBITDA

-6.39

Price/Free Cashflow

12.93

TBPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TBPH Fundamentals

TBPH Revenue

Revenue (TTM)

65.3M

Rev. Growth (Yr)

6.1%

Rev. Growth (Qtr)

-17.95%

TBPH Earnings

Earnings (TTM)

-58.3M

Earnings Growth (Yr)

-16.42%

Earnings Growth (Qtr)

12.55%

TBPH Profitability

EBT Margin

-74.08%

Return on Equity

-35.14%

Return on Assets

-16.98%

Free Cashflow Yield

7.73%

TBPH Investor Care

Shares Dilution (1Y)

2.81%

Diluted EPS (TTM)

-1.18

TBPH Alerts

Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	65.3M	0	0	0
2024	61.5M	62.0M	63.2M	64.4M
2023	51.3M	51.3M	54.5M	57.4M
2022	54.3M	52.4M	52.0M	51.3M
2021	66.3M	64.2M	59.1M	55.3M
2020	87.9M	76.8M	82.6M	71.9M
2019	57.4M	60.1M	59.7M	73.4M
2018	20.6M	40.6M	49.1M	60.4M
2017	33.3M	31.4M	16.6M	15.4M
2016	40.1M	38.5M	46.8M	48.6M
2015	31.1M	35.3M	39.7M	42.1M
2014	1.1M	4.1M	10.4M	11.7M
2013	104.3M	78.5M	52.7M	26.9M
2012	0	0	0	130.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

CEO	Mr. Rick E. Winningham M.B.A.
WEBSITE	theravance.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	111

Theravance Biopharma Inc Frequently Asked Questions

What is the ticker symbol for Theravance Biopharma Inc? What does TBPH stand for in stocks?

TBPH is the stock ticker symbol of Theravance Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Theravance Biopharma Inc (TBPH)?

As of Wed May 14 2025, market cap of Theravance Biopharma Inc is 420.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TBPH stock?

You can check TBPH's fair value in chart for subscribers.

Is Theravance Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether TBPH is over valued or under valued. Whether Theravance Biopharma Inc is cheap or expensive depends on the assumptions which impact Theravance Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TBPH.

What is Theravance Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 14 2025, TBPH's PE ratio (Price to Earnings) is -7.21 and Price to Sales (PS) ratio is 6.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TBPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Theravance Biopharma Inc's stock?

In the past 10 years, Theravance Biopharma Inc has provided -0.054 (multiply by 100 for percentage) rate of return.